Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review.

ABSTRACT:

Background and objective

Mutations located in epidermal growth factor receptor (EGFR) tyrosine kinase domains have been described as the 'Achilles heel' of non-small cell lung cancer (NSCLC) and can be targeted by epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). However, the clinical benefits of EGFR-TKIs are limited, and drug resistance inevitably occurs in NSCLC patients after long-term exposure to certain drugs. EGFR-TKI combination therapies, including combined targeted therapy, radiotherapy, chemotherapy, and immunotherapy, have shown promise in addressing this issue. This literature review analyzed the rationale and controversies of clinical research related to various EGFR-TKI combination therapies.

Methods

The PubMed database was searched to r

SUBMITTER: Zhang Q 

PROVIDER: S-EPMC10774042 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature